LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 523

Search options

  1. Article: Laparoscopic selection for surgery in epithelial ovarian cancer. A short review.

    Ghirardi, V / Fagotti, A / Scambia, G

    Facts, views & vision in ObGyn

    2023  Volume 15, Issue 1, Page(s) 25–28

    Abstract: The role of laparoscopy as a treatment selection method in ovarian cancer patients is receiving growing attention in surgical practice in both early and advanced-stage disease. When the disease is confined to the ovary, intraoperative laparoscopic ... ...

    Abstract The role of laparoscopy as a treatment selection method in ovarian cancer patients is receiving growing attention in surgical practice in both early and advanced-stage disease. When the disease is confined to the ovary, intraoperative laparoscopic assessment of the tumour features is needed to select the best surgical approach in order to prevent intraoperative spillage of cancer cells which would negatively impact patient prognosis. The role of laparoscopy as a disease distribution assessment tool in cases of advanced-stage disease is now accepted by current guidelines as an effective treatment strategy selection. Indeed, a published and validated laparoscopic scoring system, based on laparoscopic assessed intra-abdominal disease dissemination features have been demonstrated to be a reliable predictor of optimal cytoreduction achievement. This subsequently reduces the exploratory laparotomy rate in both primary and interval debulking surgery setting. Furthermore, in cases of recurrent disease, the use of laparoscopy to predict whether complete tumour resection can be achieved is accepted by available guidelines. In this setting, the combination of laparoscopy and imaging techniques to manage platinum sensitive recurrent ovarian cancer cases showed a high accuracy in appropriately selected patients for secondary cytoreductive surgery. In this article we describe the role of laparoscopy in the treatment selection-process in ovarian cancer patients.
    Language English
    Publishing date 2023-04-03
    Publishing country Belgium
    Document type Journal Article
    ZDB-ID 2701574-9
    ISSN 2032-0418 ; 2684-4230
    ISSN 2032-0418 ; 2684-4230
    DOI 10.52054/FVVO.15.1.060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Sentinel lymph node biopsy in ovarian cancer: more questions than certainties.

    Fagotti, Anna / Nero, Camilla

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2023  Volume 33, Issue 10, Page(s) 1502–1503

    MeSH term(s) Humans ; Female ; Sentinel Lymph Node Biopsy ; Ovarian Neoplasms/surgery ; Ovarian Neoplasms/pathology ; Lymph Nodes/surgery ; Lymph Nodes/pathology ; Breast Neoplasms/pathology ; Lymph Node Excision
    Language English
    Publishing date 2023-10-02
    Publishing country England
    Document type Editorial
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1136/ijgc-2023-004911
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: ASO Author Reflections: Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery.

    Ghirardi, Valentina / Trozzi, Rita / Scambia, Giovanni / Fagotti, Anna

    Annals of surgical oncology

    2024  

    Language English
    Publishing date 2024-03-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-024-15124-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.

    Peters, Inge / Marchetti, Claudia / Scambia, Giovanni / Fagotti, Anna

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2024  Volume 34, Issue 3, Page(s) 352–362

    Abstract: Precision medicine through molecular profiling has taken a prominent role in the treatment of solid tumors and it is widely expected that this will continue to expand. With respect to gynecological cancers, a major change has particularly been observed ... ...

    Abstract Precision medicine through molecular profiling has taken a prominent role in the treatment of solid tumors and it is widely expected that this will continue to expand. With respect to gynecological cancers, a major change has particularly been observed in the treatment landscape of epithelial ovarian, endometrial, and cervical cancers. Regarding the former, maintenance therapy with either poly(ADP-ribose) polymerase inhibitors (PARPi) and/or bevacizumab has become an indispensable treatment option following the traditional combination of cytoreductive surgery and platinum-based chemotherapy. Considering endometrial cancer, the molecular classification system has now been incorporated into virtually every guideline available and molecular-directed treatment strategies are currently being researched, presumably leading to a further transformation of its treatment paradigm. After all, treatment with immune-checkpoint inhibitors that target the programmed cell death 1 (PD-1) receptor has already been shown to significantly improve disease outcomes in these patients, especially in those with mismatch repair deficient, microsatellite stability-high (MMRd-MSI-H) disease. Similarly, in recurrent/metastatic cervical cancer patients, these agents elicited improved survival rates when being added to platinum-based chemotherapy with or without bevacizumab. Interestingly, implications of these targeted therapies for surgical management have been touched on to a minor extent, but are at least as intriguing. This review therefore aims to address the wide-ranging opportunities the molecular tumor characteristics and their corresponding targeted therapies have to offer for the surgical management of epithelial ovarian, endometrial, and cervical cancers, both in the primary and recurrent setting.
    MeSH term(s) Humans ; Female ; Uterine Cervical Neoplasms ; Bevacizumab ; Neoplasm Recurrence, Local ; Endometrial Neoplasms ; Precision Medicine
    Chemical Substances Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2024-03-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1136/ijgc-2023-004580
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer-A Multicenter Study.

    Fagotti, Anna

    Annals of surgical oncology

    2018  Volume 25, Issue 12, Page(s) 3709–3710

    MeSH term(s) BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Biomarkers, Tumor/genetics ; Disease Management ; Female ; Germ-Line Mutation ; Humans ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Precision Medicine
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human ; Biomarkers, Tumor
    Language English
    Publishing date 2018-09-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-018-6724-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: PARP inhibitors in epithelial ovarian cancer: what are their potential implications for surgical management?

    Peters, Inge / Marchetti, Claudia / Fagotti, Anna / Scambia, Giovanni

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

    2023  Volume 49, Issue 9, Page(s) 106973

    MeSH term(s) Humans ; Female ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/surgery ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/surgery
    Chemical Substances Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2023-06-29
    Publishing country England
    Document type Editorial
    ZDB-ID 632519-1
    ISSN 1532-2157 ; 0748-7983
    ISSN (online) 1532-2157
    ISSN 0748-7983
    DOI 10.1016/j.ejso.2023.06.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Hyperthermic intraperitoneal chemotherapy for ovarian cancer: long-term findings from the OVHIPEC-1 trial.

    Ghirardi, Valentina / Fagotti, Anna / Scambia, Giovanni

    The Lancet. Oncology

    2023  Volume 24, Issue 10, Page(s) 1057–1059

    MeSH term(s) Female ; Humans ; Combined Modality Therapy ; Cytoreduction Surgical Procedures ; Hyperthermia, Induced ; Hyperthermic Intraperitoneal Chemotherapy ; Ovarian Neoplasms/drug therapy
    Language English
    Publishing date 2023-10-04
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(23)00447-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Current and future trials about HIPEC in ovarian cancer.

    Ghirardi, Valentina / Trozzi, Rita / Scambia, Giovanni / Fagotti, Anna

    Bulletin du cancer

    2023  Volume 111, Issue 3, Page(s) 254–260

    Abstract: Due to the typical peritoneal spread of the disease, together with cytoreductive surgery and adjuvant platinum-based chemotherapy, the role of hyperthermic intraperitoneal chemotherapy (HIPEC) is gainig more interest in advanced ovarian cancer (AOC) ... ...

    Abstract Due to the typical peritoneal spread of the disease, together with cytoreductive surgery and adjuvant platinum-based chemotherapy, the role of hyperthermic intraperitoneal chemotherapy (HIPEC) is gainig more interest in advanced ovarian cancer (AOC) treatment. Indeed, the addition of hyperthemia seems to enhance the cytotoxic effect of chemotherapy directly delivered on peritoneal surface. So far, data on HIPEC administration during the primary debulking surgery (PDS) have been controversial. Indeed, despite flaws and biases, a survival advantage in a subgroup analysis of a prospective randomized trial of PDS+HIPEC treated patients was not demonstrated, whilst positive results are coming from a large retrospective cohort of patients treated with HIPEC after upfront surgery. In this setting, larger prospective data from an ongoing trial are expected by 2026. Contrariously, the addition of HIPEC with cisplatin 100mg/m
    MeSH term(s) Humans ; Female ; Hyperthermic Intraperitoneal Chemotherapy ; Retrospective Studies ; Prospective Studies ; Hyperthermia, Induced/methods ; Neoplasm Recurrence, Local/drug therapy ; Ovarian Neoplasms/surgery ; Ovarian Neoplasms/drug therapy ; Combined Modality Therapy ; Carcinoma, Ovarian Epithelial/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2023-02-28
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2023.01.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: The first European gynaecological procedure with the new surgical robot Hugo™ RAS. A total hysterectomy and salpingo-oophorectomy in a woman affected by BRCA-1 mutation.

    Monterossi, G / Pedone Anchora, L / Gueli Alletti, S / Fagotti, A / Fanfani, F / Scambia, G

    Facts, views & vision in ObGyn

    2022  Volume 14, Issue 1, Page(s) 91–94

    Abstract: Background: The benefits of minimally invasive surgery are well known in gynaecology. Robotic-assisted surgery has gained widespread acceptance within the surgical community and seems to be the most rapidly developing sector of minimally invasive ... ...

    Abstract Background: The benefits of minimally invasive surgery are well known in gynaecology. Robotic-assisted surgery has gained widespread acceptance within the surgical community and seems to be the most rapidly developing sector of minimally invasive surgery.
    Objectives: This video shows the salient steps of total hysterectomy with new robotic technology, Hugo™ RAS. The objectives were to introduce and demonstrate the feasibility, efficacy, and safety of this new advanced device.
    Materials and methods: A sixty-two years-old woman affected by BRCA-1 mutation underwent the first European gynaecological surgical procedure using the new surgical robot Hugo™ RAS in the Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
    Main outcomes measures: Docking and operative times.
    Results: The docking time was 6 minutes and the total operative time was 58 minutes. There were no system errors and faults in the robotic arms. The surgeon found no friction or rasping in the arms. The estimated blood loss was 30 mL. No intraoperative complications were recorded.
    Conclusion: Gynaecological surgery with Hugo™ RAS seems feasible, safe and effective as shown by initial experiences in urological surgery. A larger case series would confirm the current experience and determine whether this technology could offer any additional benefit.
    Language English
    Publishing date 2022-04-02
    Publishing country Belgium
    Document type Journal Article
    ZDB-ID 2701574-9
    ISSN 2032-0418 ; 2684-4230
    ISSN 2032-0418 ; 2684-4230
    DOI 10.52054/FVVO.14.1.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Medicolegal and insurance issues regarding

    Oliva, Riccardo / Grassi, Simone / Marchetti, Claudia / Cazzato, Francesca / Marinelli, Roberta / Scambia, Giovanni / Fagotti, Anna

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2024  

    Abstract: Hereditary breast and ovarian cancer syndrome is an autosomal dominant cancer susceptibility syndrome mainly due to variants ... ...

    Abstract Hereditary breast and ovarian cancer syndrome is an autosomal dominant cancer susceptibility syndrome mainly due to variants in
    Language English
    Publishing date 2024-04-19
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1136/ijgc-2023-005225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top